Get the Stockscreener App
0.98
18.67%
-0.225
Pre-market:
1.02
0.04
+4.08%
20 20 Biolabs Inc stock is traded at $0.98, with a volume of 9.38M.
It is down -18.67% in the last 24 hours and down -45.25% over the past month.
20/20 Biolabs Inc is a commercial stage diagnostics company with the core mission of developing and commercializing clinical laboratory tests for early disease detection and prevention and associated software that is powered by machine learning and real-world data to improve diagnostic accuracy and clinical utility. The company offers two OneTest lab products; OneTest for Cancer that inludes primary MCED blood test and revenue source post-COVID and OneTest for Longevity that consists of inflammatory biomarkers.
See More
Previous Close:
$1.205
Open:
$1.31
24h Volume:
9.38M
Relative Volume:
26.85
Market Cap:
$10.27M
Revenue:
$1.85M
Net Income/Loss:
$-5.26M
P/E Ratio:
-1.0368
EPS:
-0.9452
Net Cash Flow:
-
1W Performance:
-26.87%
1M Performance:
-45.25%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$0.90
$1.36
1-Week Range:
$0.90
$1.43
52-Week Range:
$0.90
$14.09
20 20 Biolabs Inc Stock (AIDX) Company Profile
Name
20 20 Biolabs Inc
Sector
Industry
Phone
(240) 453-6339
Address
9430 KEY WEST AVENUE, ROCKVILLE
Compare AIDX vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AIDX
20 20 Biolabs Inc
|
0.98 | 12.63M | 1.85M | -5.26M | 0 | -0.9452 |
ABT
Abbott Laboratories
|
87.41 | 152.88B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
316.48 | 120.18B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
78.60 | 100.34B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
57.78 | 84.95B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
85.78 | 47.91B | 6.30B | 1.07B | 1.09B | 1.8406 |
20 20 Biolabs Inc Stock (AIDX) Latest News
No Analysis Provided - StocksToTrade
AIDX Price Today: 20/20 Biolabs, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
AIDX Slides As 20/20 Biolabs Inc. Faces Heavy Selling - timothysykes.com
20/20 Biolabs Commences Emergency Planning for Ebola & Hantavirus Lab Testing if Outbreak Creates Overflow Demand - Sahm
20/20 Biolabs: Buy Rating Reiterated on Growth Outlook and OneTest Momentum; $5 Price Target Maintained - TipRanks
AIDX - Finviz
AIDX Stock Slides As 20/20 Biolabs Tests Key Support - timothysykes.com
20/20 Biolabs stock surges on Ebola testing plans - Investing.com India
20/20 Biolabs stock surges on Ebola testing plans By Investing.com - Investing.com Nigeria
20/20 Biolabs Engages Pcr Test Kit Developers For Ebola And Hantavirus Testing - TradingView
Lab that ran 400,000 COVID tests now preparing for Ebola, hantavirus - Stock Titan
20/20 Biolabs 2Q Loss/Shr 28c >AIDX - Moomoo
20/20 Biolabs (NASDAQ: AIDX) registers 10.105M shares; posts Q1 2026 results - Stock Titan
20/20 Biolabs, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
20/20 Biolabs (AIDX) posts lower Q1 revenue and deeper loss after $5M preferred raise - Stock Titan
20/20 BioLabs reports Q1 2026 revenue $0.4M, net loss $2.17M, cash $4.2M - TradingView
Q1 2026: 20/20 BioLabs (AIDX) revenue declines as cash rises on $5M raise - Stock Titan
20/20 BioLabs Reports First Quarter 2026 Financial Results and Recent Operational Progress - The Manila Times
Press Release: 20/20 BioLabs Reports First Quarter 2026 Financial Results and Recent Operational Progress - Moomoo
What Factors Led to 20/20 Biolabs' Dramatic Stock Collapse - Kavout
Maxim Group Initiates 20/20 BIOLABS INC(AIDX.US) With Buy Rating, Announces Target Price $5 - 富途牛牛
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
20/20 Biolabs (AIDX) delays 10-Q filing; expects 5-day extension - Stock Titan
AIDX SEC Filings20/20 Biolabs Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Number of shareholders of 20/20 Biolabs, Inc. – NASDAQ:AIDX - TradingView
20/20 BioLabs to Attend Sidoti Micro-Cap Virtual Conference on May 20, 2026 - ChartMill
20/20 Biolabs, Inc.Common Stock (NQ: AIDX - FinancialContent
AIDX | 20/20 Biolabs, Inc. Common FinancialsIncome Statement - Quiver Quantitative
USC inks licensing agreement for prostate cancer screening tool - University of South Carolina
20/20 BioLabs Licenses Patented Algorithm from University of South Carolina for Early Detection of Aggressive Prostate Tumors - Quiver Quantitative
20/20 BioLabs Exclusively Licenses PSA Velocity Algorithm from the University of South Carolina - The Manila Times
New PSA algorithm uses repeat blood tests to flag high-risk prostate tumors early - Stock Titan
SNGX News | SOLIGENIX INC (NASDAQ:SNGX) - ChartMill
AIDX: 20/20 Biolabs Inc.Brokerage Recommendations Chart - Zacks Investment Research
20/20 BioLabs licenses kidney disease prediction technology from ROKIT Healthcare - MSN
A. G. P. Initiates 20/20 BIOLABS INC(AIDX.US) With Buy Rating, Announces Target Price $1.46 - Moomoo
20/20 Biolabs Unchanged on News - Baystreet.ca
How 20/20 Biolabs (AIDX) integrates its acquisitions | AIDX Latest Quarter Earnings: 20/20 Biolabs withholds core EPS and revenue performance metricsViral Momentum Stocks - newser.com
AIDX Latest Quarter Earnings: 20/20 Biolabs withholds core EPS and revenue performance metricsUnderperform - newser.com
20/20 Biolabs Inc. (AIDX) Gross Margin (TTM) - Zacks Investment Research
Is 20/20 Biolabs (AIDX) stock a strong buy |Bond Issuance - newser.com
20/20 Biolabs Inc. (AIDX) - Zacks Investment Research
20/20 BioLabs blood test platform targeting early detection of hard-to-screen Cancers - Proactive financial news
20/20 Biolabs (NASDAQ: AIDX) cuts warrant price, registers 15.16M shares - Stock Titan
Warrant strike cut to $2.25 as 20/20 Biolabs (NASDAQ: AIDX) registers 10.1M shares - Stock Titan
Streeterville warrant repricing at 20/20 Biolabs (NASDAQ: AIDX) drops strike - Stock Titan
AIDX (20/20 Biolabs) highlights rising clinical test adoption as core growth driver in latest quarterly earnings.Community Trade Ideas - Newser
How to Value 20/20 Biolabs (AIDX) Stock (Technical Strength) 2026-04-22Community Driven Stock Picks - Cổng thông tin điện tử Tỉnh Sơn La
20/20 BIOLABS INC Company Profile & Introduction - Moomoo
AIDX | 20/20 Biolabs, Inc. Common Insider Trading - Quiver Quantitative
20/20 Biolabs (AIDX) Stock Chart and Price History 2026 - MarketBeat
20 20 Biolabs Inc Stock (AIDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.22%
1.41%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):